Alkermes plc. (ALKS)

Insider Trading Filed: 2026-04-13

Key Insights

Nancy Lurker, a director of Alkermes plc., exercised 3,751 restricted stock units and sold 901 shares, indicating some insider activity.
The transaction was executed on April 11, 2026, suggesting recent insider involvement with the company.
The sale price of $33.36 per share was in line with the current market price, suggesting the transaction was not an attempt to take advantage of any informational edge.

Insider Trading Filed: 2026-04-06

Key Insights

The reporting person, David Joseph Gaffin, sold 2,034 ordinary shares of Alkermes plc. (ALKS) on April 6, 2026, at a price of $34.57 per share.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
Following the reported transaction, the reporting person continues to beneficially own 233,592 ordinary shares of Alkermes plc. (ALKS).

Insider Trading Filed: 2026-02-20

Key Insights

Insider David Joseph Gaffin, an Executive VP and Chief Legal Officer at Alkermes, exercised 6,355 and 7,673 restricted stock units in consecutive transactions on February 18 and 19, 2026, respectively.
Gaffin disposed of 2,126 and 3,407 ordinary shares through withholding transactions to cover tax liabilities on the vesting of the restricted stock units.
After the reported transactions, Gaffin beneficially owns 231,602 ordinary shares of Alkermes, indicating his continued commitment to the company.

Insider Trading Filed: 2026-02-20

Key Insights

The reporting person, Craig C. Hopkinson, is an executive officer (EVP R&D, Chief Medical Officer) of Alkermes plc., indicating insider trading activity.
Hopkinson acquired 8,897 ordinary shares through the vesting of restricted stock units on 2/18/2026 and 7,673 ordinary shares through the vesting of restricted stock units on 2/19/2026.
Hopkinson also disposed of 3,504 ordinary shares on 2/18/2026 and 3,407 ordinary shares on 2/19/2026, likely for tax withholding purposes.

Insider Trading Filed: 2026-02-20

Key Insights

Insider Blair C. Jackson, the Executive Vice President and Chief Operating Officer, has exercised 18,197 restricted stock units and disposed of 7,926 ordinary shares through withholding for tax purposes.
The transactions occurred on February 18 and 19, 2026, suggesting the executive is managing their position in the company.
The remaining 27,903 restricted stock units still held by the insider indicate ongoing equity compensation and potential for future transactions.

Insider Trading Filed: 2026-02-20

Key Insights

Christian Todd Nichols, the SVP and Chief Commercial Officer of Alkermes plc. (ALKS), exercised 12,400 restricted stock units and sold 4,146 shares to cover tax withholding obligations, indicating ongoing executive confidence in the company's performance.
The reported transactions occurred on February 18 and 19, 2026, suggesting a regular pattern of insider activity at Alkermes.
The net shares retained by Nichols after the transactions represent a significant ownership stake, aligning his interests with those of shareholders.

Insider Trading Filed: 2026-02-20

Key Insights

The reporting person, Samuel Joseph Parisi, is a VP (Interim PAO) at Alkermes plc. (ALKS), indicating an important role and potential access to insider information.
Parisi exercised 2,034 and 2,991 restricted stock units on February 18 and 19, 2026, respectively, suggesting he is taking some gains but still holds a significant stake of 11,057 ordinary shares.
The shares acquired through the restricted stock unit exercises were partially sold, with 706 shares sold on February 18 and 979 shares sold on February 19, suggesting some diversification of Parisi's position.

Current Report Filed: 2026-02-12

Key Insights

Alkermes entered into a $1.525 billion term loan credit facility to fund its acquisition of Avadel Pharmaceuticals.
The credit facility includes a $750 million term loan A and a $775 million term loan B, with maturities in 2031.
The acquisition of Avadel Pharmaceuticals, a wholly owned subsidiary, suggests Alkermes is diversifying its product portfolio and expanding its market reach.

Insider Trading Filed: 2026-02-06

Key Insights

The reporting person, David Joseph Gaffin, is an executive officer (EVP, CLO) at Alkermes, Inc., a subsidiary of Alkermes plc.
Gaffin acquired 25,352 ordinary shares of Alkermes plc. through the vesting of performance-based restricted stock unit awards, indicating alignment with the company's long-term performance.
Gaffin also disposed of 7,619 ordinary shares, likely for tax withholding purposes, suggesting continued confidence in the company's prospects.

Insider Trading Filed: 2026-02-06

Key Insights

The reporting person, Craig C. Hopkinson, an EVP R&D and Chief Medical Officer of Alkermes plc., acquired 25,352 ordinary shares as a result of the vesting of performance-based restricted stock unit awards granted in 2023.
Hopkinson also sold 7,454 ordinary shares, likely for tax withholding purposes, at a price of $33.55 per share.
The reported transactions suggest the reporting person continues to maintain a significant direct ownership stake of 75,638 ordinary shares in the company.

Insider Trading Filed: 2026-02-06

Key Insights

The reporting person, Blair C. Jackson, who is the EVP and Chief Operating Officer of Alkermes plc., acquired 28,810 ordinary shares of the company through the vesting of performance-based restricted stock unit awards, indicating management's confidence in the company's performance.
The reporting person also disposed of 8,626 ordinary shares, likely for tax purposes, maintaining a net increase in his beneficial ownership of Alkermes plc. shares.
The vesting of the performance-based restricted stock units was triggered by the achievement of certain pre-specified performance goals and the application of a relative total shareholder return modifier, suggesting the company has met its strategic objectives.

Insider Trading Filed: 2026-02-06

Key Insights

Christian Todd Nichols, the SVP and Chief Commercial Officer of Alkermes plc., acquired 21,127 ordinary shares through the vesting of performance-based restricted stock units, indicating his continued commitment to the company.
Nichols also disposed of 6,389 ordinary shares, likely to cover tax withholding obligations, suggesting he is maintaining a significant ownership stake in the company.
The vesting of the performance-based restricted stock units was triggered by the achievement of pre-specified goals, aligning Nichols' compensation with the company's performance.

Insider Trading Filed: 2026-02-06

Key Insights

The reporting person, Richard F. Pops, who is the Director and CEO of Alkermes plc, has acquired 149,580 ordinary shares of the company as a result of the vesting of performance-vesting restricted stock unit awards granted in 2023.
Pops has also disposed of 62,230 ordinary shares, likely for tax purposes, at a price of $33.55 per share.
The total number of ordinary shares beneficially owned by Pops following these transactions is 1,377,740, indicating a significant ownership stake in the company.

Current Report Filed: 2026-01-12

Key Insights

Alkermes plc provided preliminary, unaudited revenue estimates for the year ended December 31, 2025, indicating potential growth or decline that investors should monitor.
The company is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, which could provide additional insights into the company's financial performance and outlook.
Investors should review the corporate presentation, when available, for more details on the company's financial results and any potential impact on the stock price.

Insider Trading Filed: 2026-01-08

Key Insights

The reporting person, Craig C. Hopkinson, is an EVP of R&D and Chief Medical Officer at Alkermes plc, indicating he is an insider with significant influence.
The reporting person exercised 5,000 stock options at $19.34 per share and then sold 5,000 ordinary shares at an average price of $30.00, suggesting he is actively managing his equity position.
The transactions were conducted pursuant to a Rule 10b5-1 trading plan, which provides a safe harbor for insider trading and suggests a degree of pre-planning in the trading activity.

Insider Trading Filed: 2026-01-02

Key Insights

Craig C. Hopkinson, the EVP of R&D and Chief Medical Officer of Alkermes plc., sold 4,000 ordinary shares on 01/02/2026 at $28 per share, reducing his direct beneficial ownership to 61,740 shares.
This sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating a planned and structured approach to the transaction.
Insider selling can be a signal of management's confidence in the company's outlook, though the relatively small size of this transaction suggests it may not be a major event.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information